VTCN1 anticorps (APC)

N° du produit ABIN2656873

Détail du produit anti-VTCN1 anticorps (APC)

Antigène: VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))

Reactivité: Souris

Hôte: Hamster arménien

Clonalité: Monoclonal

Conjugué: Cet anticorp VTCN1 est conjugé à/à la APC

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

Clone: HMH4-5G1

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C

Détails sur VTCN1

Antigène: VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))

Autre désignation: B7-H4 B7S1 (VTCN1 Produits)

Synonymes: anticorps B7h4, anticorps B7s1, anticorps B7x, anticorps BC032925, anticorps B7-H4, anticorps B7H4, anticorps B7S1, anticorps B7X, anticorps B7h.5, anticorps PRO1291, anticorps VCTN1, anticorps RGD1311204, anticorps V set domain containing T cell activation inhibitor 1 L homeolog, anticorps V-set domain containing T cell activation inhibitor 1, anticorps V-set domain containing T-cell activation inhibitor 1, anticorps V set domain containing T cell activation inhibitor 1, anticorps vtcn1.L, anticorps VTCN1, anticorps vtcn1, anticorps Vtcn1

Sujet: B7-H4 is a newly discovered B7 family member that negatively regulates T cell immunity. In vitro, B7-H4 inhibits CD4+ and CD8+ T cell proliferation, cytokine production, and generation of alloreactive cytotoxic T-cells (CTLs). In vivo, blockage of endogenous B7-H4 by specific monoclonal antibodies promotes T cell responses. A new reported function of B7-H4 is as an important negative regulator of innate immunity through growth inhibition of neutrophils. It has been reported that B7-H4 is not constitutively expressed on peripheral tissues but can be induced to express on T cells, B cells, macrophages, and dendritic cells. B7-H4 is expressed on some tumor cancer cells. The role of B7-H4 in tumor progression may be to transform precancerous cells and then protect them from immunosurveillance. Although B- and T-lymphocyte attenuator (BTLA) was proposed to be the receptor for B7-H4, further studies are needed to identify the inhibitory receptor of B7-H4.